Maryland Board of Pharmacy Public Board Meeting

<u>Agenda</u> July 18, 2018

Name	Title	Present	Absent
Ashby, D.	Commissioner		
Bouyoukas, E	Commissioner		
Evans, K.	Commissioner		
Hardesty, J.	Commissioner/Treasurer		
Laws, Jr	Commissioner		
Leikach, N.	Commissioner		
Morgan, K.	Commissioner/President		
Oliver, B	Commissioner		
Peters, R.	Commissioner		
Toney, R.	Commissioner/Secretary		
Yankellow, E.	Commissioner		
Bethman, L.	Board Counsel		
Felter, B.	Staff Attorney		
Speights-Napata, D.	Executive Director		
Fields, E.	Deputy Director / Operations		
Evans, T.	Compliance Director		
Brand, E.	Licensing Manager		
Logan, B.	Legislative Liaison		
Chew, C.	Management Associate		
J			

Sunject		2 30485501	(1200- g -100 10)
	1	,	
I. Executive Committee Report(s)	A.) K. Morgan, Board President	Members of the Board with a conflict of interest relating to any item on the agenda are advised to notify the Board at this time or when the issue is addressed in the agenda.	
		1. Call to Order	
		2. Sign-in Introduction and of meeting attendees – (Please indicate on sign-in sheet if you are requesting CE Units for attendance)	
		3. Distribution of Agenda and packet materials	
	B.) R. Tony, Secretary	4. Review and approve June 2018 Public Meeting Minutes	
II. A. Executive Director Report	D. Speights- Napata, Executive Director	Operations Updates Meetings Update Contraception Regulation Meeting Summary II. Draft Tech-Check-Tech Regulations	
B. Operations	E. Fields, Deputy Director/ Operations	 Administration and Public Support (APS) Unit Updates b) June 2018 Financial Statements Management Information Systems (MIS) Unit Updates None 	
C. Licensing	E. Brand, Licensing Manager	1. Unit Updates 2. Monthly Statistics	
		License Type New Renewed Reinstated Total	
		Distributor 17 0 0 1,272	

Discussion

Action Due Date

(Assigned To)

Responsible Party

Subject

Subject	Responsible Party			Discussion			Action Due Date (Assigned To)
D. Compliance	T. Evans, Compliance Director	Pharmacy Pharmacist Vaccination Pharmacy Intern - Graduate Pharmacy Intern - Student Pharmacy Technician Pharmacy Technician- Student TOTAL 1. Unit Upd 2. Monthly Complaints & In: New Complaints & In: New Complaints Resolved (Included Actions within Capital disciplinary Summary Action Average days to	Statistics vestigation - 27 ling Carryo Goal – 27/5 y actions tans Taken –	45 416 6 0 19 312 0 798 ns: over) - 58 8 aken - 9 2	0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	2,089 11,700 4,560 57 958 9,758 21 30,415	(Assigned To)
		Average days to	complete -	- 107/			

Subject	Party	Discussion	(Assigned To)
		Inspections: Total - 131 Annual Inspections -123 Opening Inspections -4 Closing Inspections -2 Relocation/Change of Ownership Inspections -0 Board Special Investigation Inspections - 2	
E. Legislation & Regulations	B. Logan, Legislation and Regulations Manager	Regulations COMAR 10.34.05.05 Security Responsibilities COMAR 10.34.32.03 D Requirements to Administer Vaccinations COMAR 10.34.40 Pharmacist Prescribing and Dispensing Contraceptives Legislation 2019 Legislative Proposals	
III. Committee Reports A. Practice Committee	R. Peters, Chair	1. Question Presented: I am attempting to clarify if it is required by MD law for a pharmacist to provide oversight in the dispensing of oral contrast orders? The Joint Commission makes an exception where pharmacist oversight is not required but since this is considered a legend medication at federal level I was looking at MD law on this matter.	

Action Due Date

Responsible

Subject	Responsible Party	Discussion	Action Due Date (Assigned To)
		The particular product in question is an oral barium sulfate 2% contrast agent Readicat 2 ndc# 32909-0724-03	
		2. Protocol for Commissioner Acting on Behalf of the Board	
		Committee recommendations: 1. Title should be changed from "Commissioner Protocol" to "Commissioner/Staff Protocol" 2. Description:	
		2. Remove all references to liability in Section C3. Board counsel should be consulted for legal review prior to a presentation that may raise potential issues	
		4. References in the protocol should be to a position, not to a person	
B. Licensing Committee	D. Ashby, Chair	 Review of Pharmacist Applications: Review of Pharmacy Intern Applications: 	
		3. Review of Pharmacy Technician Applications:	
		4. Review of Distributor Applications:5. Review of Pharmacy Applications:	
		6. Review of Pharmacy Technicians Training Programs:	
		7. New Business: a. Technician Training Program – Does a pharmacy need to apply for and pay the application fee for a Technician Training program previously approved by the Board for another pharmacy?	

	Licensing Committee's Recommendation: B. Felter to provide guidance at Board meeting. NEIL LEIKACH RECUSED b. KJP - Requests the Board reconsider its denial of the refund for her Pharmacist renewal, as her application was not processed. It was not processed because she did not provide CE's.	
	 B. Felter to provide guidance at Board meeting. NEIL LEIKACH RECUSED b. KJP - Requests the Board reconsider its denial of the refund for her Pharmacist renewal, as her application was not processed. It was not processed because she did not provide CE's. 	
	the refund for her Pharmacist renewal, as her application was not processed. It was not processed because she did not provide CE's.	
	The Board voted to deny her request at the May 2018 Board meeting. Licensing Committee's Recommendation: Deny	
Yankellow, nair	Public Relations Committee Update:	
Morgan, nair	Disciplinary Committee Update	
	Emergency Preparedness Task Force Update	
Morgan, esident		
Morgan, resident	A. The Public Meeting was adjourned. B. K. Morgan convened a Closed Public Session to conduct a medical review committee evaluation of confidential applications. C. The Closed Public Session was adjourned. Immediately thereafter, K. Morgan convened an Administrative Session for	
M nai M resi	organ, forgan, dent forgan,	Iorgan, Temergency Preparedness Task Force Update Emergency Preparedness Task Force Update Iorgan, Ident Iorgan, Ident B. K. Morgan convened a Closed Public Session to conduct a medical review committee evaluation of confidential applications. C. The Closed Public Session was adjourned. Immediately

Subject	Responsible Party	Discussion	Action Due Date (Assigned To)
		D. With the exception of cases requiring recusals, the Board members present at the Public Meeting continued to participate in the Closed Public Session and the Administrative Session.	